ReviewAntibiotics (Basel, Switzerland)2022
Azithromycin through the Lens of the COVID-19 Treatment.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- One Health Insights From Pteropus medius: Nipah Virus Spillover, Microbiota, and Antimicrobial Resistance.MicrobiologyOpen · 2026Review
- Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.Therapeutic innovation & regulatory science · 2026Review
- Prenatal Azithromycin Exposure and Risk of Neurodevelopmental Disorders in Children.JAMA network open · 2026Article
- Evaluating adverse events of antibacterials in infants: insights from FDA adverse event reporting system (FAERS) data.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Resistance Paradox in COVID-19 Ventilator-Associated Pneumonia: A Retrospective Study on Rapid Molecular Stewardship.Antibiotics (Basel, Switzerland) · 2026Article
- Risk of drug eruption associated with the use of tetracyclines, macrolides, and fluoroquinolones: real-world evidence from a pharmacovigilance study utilizing the FDA adverse event reporting system.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- An assessment of antimicrobial resistance national action plans and their impact on antibiotic use.BMJ global health · 2025Article
- Environmental factors driving antimicrobial resistance in Indian flying foxes (Pteropus medius): one health implications.Scientific reports · 2025Article
- The impact of the COVID-19 pandemic on antimicrobial usage: an international patient-level cohort study.JAC-antimicrobial resistance · 2025Article
- The Protective Role of Folic Acid in Biochemical and Histopathological Changes Induced by Azithromycin in the Livers of Pregnant Albino Rats.Medicina (Kaunas, Lithuania) · 2025Article
- Ethiopian antimicrobial consumption trends in human health sector: A surveillance report 2020-2022.PloS one · 2025Article
- Assessment of azithromycin-induced toxicity inToxicology reports · 2024Article
- A Nationwide Evaluation of Antibiotic Consumption in Kazakhstan from 2019 to 2023.Antibiotics (Basel, Switzerland) · 2024Article
- Epidemiology and Impact of Anti-Pneumococcal Vaccination and COVID-19 on Resistance ofAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic utilization patterns in Tanzania: a retrospective longitudinal study comparing pre- and intra-COVID-19 pandemic era using Tanzania Medicines and Medical Devices Authority data.JAC-antimicrobial resistance · 2024Article
- In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice.International journal of molecular sciences · 2024Article
- Article
- Occurrence of COVID-19 in cystic fibrosis patients: a review.Frontiers in microbiology · 2024Review
- Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.Signal transduction and targeted therapy · 2023Review
- Prognostic Value of Routine Biomarkers in the Early Stage of COVID-19.Healthcare (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Azithromycin has become famous in the last two years, not for its main antimicrobial effect, but for its potential use as a therapeutic agent for COVID-19 infection. Initially, there were some promising results that supported its use, but it has become clear that scientific results are insufficient to support such a positive assessment. In this review we will present all the literature data concerning the activity of azithromycin as an antimicrobial, an anti-inflammatory, or an antivirus agent. Our aim is to conclude whether its selection should remain as a valuable antivirus agent or if its use simply has an indirect therapeutic contribution due to its antimicrobial and/or immunomodulatory activity, and therefore, if its further use for COVID-19 treatment should be interrupted. This halt will prevent further antibiotic resistance expansion and will keep azithromycin as a valuable anti-infective therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.